AB0277 DYSLIPIDEMIA TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS USING bDMARDs IS BETTER THAN PsA, BUT THERE IS STILL A WAY TO GO
Authors: G. Sandal Uzun, O. D. Tatar, N. E. Gezerer, E. Bilgin, G. K. Yardimci, E. C. Bolek, B. Farisogullari, E. Duran, Z. Özsoy, G. Ayan, M. Ekici, E. Unaldi, L. Kiliç, A. Akdoğan, O. Karadag, Ş. A. Bilgen, S. Kiraz, U. Kalyoncu, A. İ. Ertenli
Journal: Annals of the Rheumatic Diseases (2022)

Background Patients with inflammatory arthritis have an increased risk of cardiovascular disease. Dyslipidemia is one of the primary modifiable risk factors. Objectives Comparasion of the frequency of dyslipidemia and the use of anti-hyperlipidemic agents in patients with Rheumatoid Arthritis (RA) and Psoriatic arthritis (PsA) receiving bDMARDs. Methods The Hacettepe University biological database (HUR-BIO), was established in 2005 and 581 (75.4% female) patients with RA and 520 (69.4% female) patients with PsA enrolled up to 2021 were analyzed. Dyslipidemia was defined according to the Turkish Endocrine and Metabolism society criteria (TC &gt; 240, Triglycerides (Tg) &gt; 150, LDL-C &gt; 160, HDL-C (&lt; 40 in men, &lt; 50 in women) (1). The anti-hyperlipidemic (anti-HL) agents used by the patients during follow-up and at their last visit were recorded. Results The mean (SD) age of the patients and diseases duration were as follows; RA vs. PsA [age: 52.1 (13.9) vs. 48.7 (12.5) years; disease duration: 5.3 (2.1) vs. 9.2 (6.4) years]. Lipid profiles were known in 289 (49.7%) patients with RA and in 175 (33.6%) patients with PsA at the initiaiton of bDMARD. Lipid profiles were evaluated in 356 (61.2%) patients with RA and 226 (43.4%) patients with PsA during follow-up and at the last visit. Lipid profiles were similar in patients with RA and PsA at the initiation of bDMARDs (Table 1). At the initiation of bDMARD, 29 (5.0%) of RA patients and 10 (3.2%) of PsA patients were receiving anti-HL agents. During the entire follow-up, 65 (12.6%) patients with RA and 22 (4.8%) patients with PsA have used anti-HL agents (p&lt;0.001). Table 1. Lipid values in patients with RA and PsA at the initiation of bDMARD and at the last visit Rheumatoid arthritis, n (%) Psoriatic arthritis, n (%) p1* p2** Lipid values bDMARD initiation Last visit bDMARD initiation Last visit Total Cholesterol&gt; 240 47/270(17.4) 98/339 (28.9) 32/161(19.8) 57/203 (28.1) 0.30 0.13 Triglyseride&gt; 150 62/242 (25.6) 108/320 (33.7) 45/159 (28.3) 80/193 (41.4) 0.79 0.20 HDL-C&lt; 40 (males),&lt; 50 (females) 88/267 (32.9) 70/343 (20.4) 57/157 (36.3) 20/207 (9.6) 0.48 0.001 LDL-C &gt; 160 53/289 (18.3) 91/356 (25.6) 43/175 (24.5) 65/226 (28.7) 0.38 0.55 *p1, bDMARD initiation visit comparison **p2, last visit comparison Conclusion In real-life cohort, lipid profile was not assesed in half of the patients during entire follow-up. Although, LDL-C levels are high in about a quarter of the patients in both groups, use of anti-hyperlipidemic drug was inadequate. This is even more evident in PsA patients. Despite the significant emphasis on comorbidities in treatment guidelines, there is still a long way to go in real life. References [1]TEMD Obesity Guideline, L.M., Hypertension Working Group, TEMD Dyslipidemia Diagnosis and Treatment Guideline. 9 th ed. 2021, Disclosure of Interests None declared